The following IPOs are expected to price this week:
Caesars Entertainment (CZR), a casino entertainment provider owned by TPG and Apollo, plans to raise $16 million by offering 1,811,313 shares at a price range of $8.00 to $10.00. At the midpoint of the proposed range, Caesars Entertainment will command a market value of $1.14 billion. Caesars Entertainment, which was founded in 1989, booked $8.8 billion in sales over the last 12 months. The Las Vegas, NV-based company plans to list on the NASDAQ under the symbol CZR. Credit Suisse, Citi, and BofA Merrill Lynch are the lead underwriters on the deal.
Cementos Pacasmayo SAA (CPAC), which produces and distributes cement for construction in Peru, plans to raise $245 million by offering 20,000,000 shares at a price range of $11.50 to $13.00. At the midpoint of the proposed range, Cementos Pacasmayo SAA will command a market value of $1.39 billion. Cementos Pacasmayo SAA, which was founded in 1949, booked $349 million in sales over the last 12 months. The Lima, Peru-based company plans to list on the NYSE under the symbol CPAC. J.P. Morgan is the lead underwriter on the deal. Please note: We are not issuing research on this IPO.
Ceres (CERE), which sells seeds used to produce renewable bioenergy feedstocks, plans to raise $110 million by offering 5,000,000 shares at a price range of $21.00 to $23.00. At the midpoint of the proposed range, Ceres will command a market value of $550.30 million. Ceres, which was founded in 1996, booked $7 million in sales over the last 12 months. The Thousand Oaks, CA-based company plans to list on the NASDAQ under the symbol CERE. Goldman, Sachs & Co. and Barclays Capital are the lead underwriters on the deal.
ChemoCentryx (CCXI), which is developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo, plans to raise $60 million by offering 4,000,000 shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, ChemoCentryx will command a market value of $554.76 million. ChemoCentryx, which was founded in 1997, booked $19 million in sales over the last 12 months. The Mountain View, CA-based company plans to list on the NASDAQ under the symbol CCXI. J.P. Morgan and Citi are the lead underwriters on the deal.
EPAM Systems (EPAM), an offshore IT services provider with delivery centers in Eastern Europe, plans to raise $126 million by offering 7,400,000 shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, EPAM Systems will command a market value of $777.86 million. EPAM Systems, which was founded in 1993, booked $310 million in sales over the last 12 months. The Newtown, PA-based company plans to list on the NYSE under the symbol EPAM. Citi, UBS Investment Bank, and Barclays Capital are the lead underwriters on the deal.
FX Alliance (FX), which operates a leading independent, institutional foreign exchange trading platform, plans to raise $75 million by offering 5,200,000 shares at a price range of $13.50 to $15.50. At the mid-point of the proposed range, FX Alliance will command a market value of $425.56 million. FX Alliance, which was founded in 2000, booked $114 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol FX. BofA Merrill Lynch, Goldman, Sachs & Co., and Citi are the lead underwriters on the deal.
GSE Holding (GSE), a global maker of containment products for mining, waste and water managemen, plans to raise $63 million by offering 7,000,000 shares at a price range of $8.00 to $10.00. At the midpoint of the proposed range, GSE Holding will command a market value of $175.97 million. GSE Holding was founded in 1981. The Houston, TX-based company plans to list on the NYSE under the symbol GSE. Oppenheimer & Co., William Blair, and FBR Capital Markets are the lead underwriters on the deal. Please note: Relaunched after postponing on 12/15/11. Prior terms 9 million shares at $13 to $15.
Roundy's (RNDY), a midwest supermarket chain with 158 stores in Wisconsin, Minnesota and Illinois, plans to raise $200 million by offering 18,181,818 shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Roundy's will command a market value of $456.30 million. Roundy's, which was founded in 1872, booked $3.8 billion in sales over the last 12 months. The Milwaukee, WI-based company plans to list on the NYSE under the symbol RNDY. Credit Suisse, J.P. Morgan, and Jefferies & Co. are the lead underwriters on the deal.
Synacor (SYNC), which enables cable/telecom service providers to offer consumers online content/services, plans to raise $75 million by offering 6,818,170 shares at a price range of $10.00 to $12.00. At the mid-point of the proposed range, Synacor will command a market value of $326.45 million. Synacor, which was founded in 1998, booked $80 million in sales over the last 12 months. The Buffalo, NY-based company plans to list on the NASDAQ under the symbol SYNC. BofA Merrill Lynch and Citi are the lead underwriters on the deal.
TVAX Biomedical (TVAX), a biotech company focused on cancer cell vacination and T cell cancer treatment, plans to raise $20 million by offering 2,000,000 shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, TVAX Biomedical will command a market value of $80.93 million. TVAX Biomedical, which was founded in 2004, has not yet booked any operating revenues. The Lenexa, KS-based company plans to list on the NASDAQ under the symbol TVAX. Roth Capital is the lead underwriter on the deal. Please note: We are not issuing research on this IPO.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 5 IPO pricings. Greenway Medical Technologies (GWAY), which provides integrated IT solutions and services to US physicians, was the week's winner, ending up 33% from its IPO price.
